Cadrenal Therapeutics, Common Stock Today
| CVKD Stock | 19.37 0.13 0.67% |
PerformanceModest
| Odds Of DistressAverage
|
Cadrenal Therapeutics, is trading at 19.37 as of the 25th of March 2025, a 0.67 percent decrease since the beginning of the trading day. The stock's lowest day price was 19.23. Cadrenal Therapeutics, has 51 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. The performance scores are derived for the period starting the 25th of December 2024 and ending today, the 25th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of January 2023 | Category Healthcare | Classification Health Care |
Cadrenal Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 1.88 M outstanding shares of which 41.48 K shares are currently shorted by private and institutional investors with about 0.71 trading days to cover. More on Cadrenal Therapeutics, Common
Moving together with Cadrenal Stock
Moving against Cadrenal Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cadrenal Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman CEO | Quang Pham | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
| Cadrenal Therapeutics, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cadrenal Therapeutics,'s financial leverage. It provides some insight into what part of Cadrenal Therapeutics,'s total assets is financed by creditors. | ||||||||||||||||||||||||||||||||||||
Cadrenal Therapeutics, Common (CVKD) is traded on NASDAQ Exchange in USA. It is located in 822 A1A North, Ponte Vedra, FL, United States, 32082 and employs 4 people. Cadrenal Therapeutics, is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 36.65 M. Cadrenal Therapeutics, conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.88 M outstanding shares of which 41.48 K shares are currently shorted by private and institutional investors with about 0.71 trading days to cover.
Cadrenal Therapeutics, generates negative cash flow from operations
Check Cadrenal Therapeutics, Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Cadrenal Therapeutics, is USD36.65 Million. Cadrenal Therapeutics, Common retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Cadrenal Ownership Details
Cadrenal Therapeutics, Historical Income Statement
Cadrenal Stock Against Markets
Cadrenal Therapeutics, Corporate Management
| Jeff Cole | Chief Officer | Profile | |
| FACC FAHA | Chief Officer | Profile | |
| MD FACC | Chief Officer | Profile | |
| Jeffrey Cole | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cadrenal Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cadrenal Therapeutics,. If investors know Cadrenal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cadrenal Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cadrenal Therapeutics, is measured differently than its book value, which is the value of Cadrenal that is recorded on the company's balance sheet. Investors also form their own opinion of Cadrenal Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Cadrenal Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cadrenal Therapeutics,'s market value can be influenced by many factors that don't directly affect Cadrenal Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cadrenal Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Cadrenal Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cadrenal Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.